Učitavanje...

Burosumab: A new drug to treat hypophosphatemic rickets

Burosumab (KRN23) is a fully human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets. A report enclosed in this letter gives a brief review of current knowledge on buro...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Sudan J Paediatr
Glavni autor: Kutilek, Stepan
Format: Artigo
Jezik:Inglês
Izdano: Discover Publishing Group 2017
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5845463/
https://ncbi.nlm.nih.gov/pubmed/29545670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.24911/SJP.2017.2.11
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!